



(11)

EP 3 052 096 B8

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
C07D 471/04 ^(2006.01) **A61P 35/00** ^(2006.01)
C07D 487/04 ^(2006.01) **A61K 31/519** ^(2006.01)
A61K 31/437 ^(2006.01)

(48) Corrigendum issued on:
07.03.2018 Bulletin 2018/10

(86) International application number:
PCT/US2014/059197

(45) Date of publication and mention
of the grant of the patent:
17.01.2018 Bulletin 2018/03

(87) International publication number:
WO 2015/051341 (09.04.2015 Gazette 2015/14)

(21) Application number: **14850964.9**

(22) Date of filing: **03.10.2014**

(54) **INHIBITORS OF ERK AND METHODS OF USE**

INHIBITOREN VON ERK UND VERFAHREN ZUR VERWENDUNG

INHIBITEURS D'ERK ET MÉTHODES D'UTILISATION

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

- **REN, Pingda**
San Diego, CA 92130 (US)
- **LIU, Yi**
San Diego, CA 92130 (US)

(30) Priority: **03.10.2013 US 201361886552 P**
01.08.2014 US 201462032446 P

(74) Representative: **Kremer, Simon Mark et al**
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE (GB)

(43) Date of publication of application:
10.08.2016 Bulletin 2016/32

(56) References cited:
EP-A1- 2 455 381 WO-A1-2008/156739
WO-A2-2012/170845 WO-A2-2014/179154
US-A- 3 984 556 US-A- 4 042 704
US-A- 5 116 843 US-A1- 2008 227 767
US-A1- 2010 056 800 US-B1- 6 596 726

(60) Divisional application:
17204999.1

(73) Proprietor: **Kura Oncology, Inc.**
San Diego, CA 92121 (US)

(72) Inventors:

- **LI, Liansheng**
San Diego, CA 92130 (US)
- **WU, Tao**
Carlsbad, CA 92009 (US)
- **FENG, Jun**
San Diego, CA 92130 (US)

- **DATABASE PUBCHEM [Online] 01 December**
2012 'SCHEMBL7846632', XP055331725
Retrieved from NCBI Database accession no. CID
70205837
- **DATABASE PUBCHEM [Online] 04 December**
2007 'SCHEMBL7879101', XP055331726
Retrieved from NCBI Database accession no. CID
18347999

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 052 096 B8

- TSURUO, T ET AL.: 'Platelet aggregation in the formation of tumor metastasis.' PROCEEDINGS OF THE JAPAN ACADEMY, SERIES B vol. 84, no. 6, 2008, pages 189 - 198, XP055331728 Retrieved from the Internet:
<URL:https://www.jstage.jst.go.jp/article/pjab/84/6/84_6_189/_pdf> [retrieved on 2014-11-26]
- DATABASE PUBCHEM [Online] 08 February 2007
'4A-AZONIA-5,6,7,8-TETRAHYDROANTHRACENE', XP055331729 Retrieved from NCBI Database
accession no. CID 13481918